Iterum Therapeutics has secured FDA approval for its Orlynvah (sulopenem etzadroxil and probenecid) to treat uncomplicated urinary tract infections (uUTIs) in adult women. This is the first FDA-approved product for Iterum and offers a new treatment option for women with limited alternative oral antibacterial treatment options. The approval was based on two successful Phase 3 clinical trials demonstrating Orlynvah’s safety and efficacy compared to existing treatments.
Scientists have discovered potent antibacterial substances produced by microbes in the Arctic Ocean, offering a potential solution to the growing problem of antibiotic resistance. These compounds, derived from actinobacteria, could represent a new class of antibiotics to combat increasingly resistant bacteria.
A new study reveals that the dangerous gut bacterium Clostridioides difficile (C. diff) can quickly develop resistance to vancomycin, the primary antibiotic used to treat infections. However, this resistance comes with tradeoffs for the bacteria, making it less efficient at growing and spreading. The findings highlight the urgent need for careful monitoring of antibiotic resistance in hospitals to prevent the emergence of untreatable C. diff infections.
The world is grappling with the rising threat of antibiotic-resistant bacteria, a silent pandemic that has already claimed millions of lives. Researchers are exploring innovative approaches to combat this crisis, aiming to restore the effectiveness of existing antibiotics and develop new treatments. This article explores the mechanisms behind antibiotic resistance, the challenges it poses, and the promising strategies being developed to fight back.
Despite their effectiveness in treating chronic wounds, maggots remain underutilized due to negative perceptions. This article explores the benefits of maggot therapy, challenges in public acceptance, and strategies to promote its use, including public engagement campaigns and media portrayal.
A new meta-analysis has identified cesarean delivery and antibiotic use as significant drivers of antibiotic resistance genes in infants. The study highlights the need for interventions to reduce antibiotic resistance in this vulnerable population.
Antimicrobial resistance (AMR) is a global health emergency, with drug-resistant infections killing over 1.27 million people annually. Infants are particularly susceptible to AMR due to their immature immune systems and diverse gut microbiota. This study analyzed data from 1,275 infants in 10 countries to investigate the factors influencing antibiotic resistance gene (ARG) load and mobile genetic element (MGE) abundance in the gut.
The results showed that antibiotic use, cesarean delivery, and prematurity were significantly associated with increased ARG and MGE abundance and reduced beneficial gut microbe diversity. Vaginal birth, on the other hand, was linked to lower ARG abundance but higher ARG diversity. The study also identified Escherichia coli as the main host of ARGs in the infant gut, with nearly half of the ARGs co-localized with plasmids, enabling efficient transfer between bacteria. The authors emphasized the urgent need for targeted interventions, such as probiotics, to reduce antibiotic resistance in infants and address the global AMR crisis.
